東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Active transport and CNS delivery of...

University of Minnesota., Pharmaceutics.

Linked to FindBook

Google Book

Amazon

博客來

Active transport and CNS delivery of novel tyrosine kinase inhibitors.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Active transport and CNS delivery of novel tyrosine kinase inhibitors./
Author:	Chen, Ying.
Description:	209 p.
Notes:	Adviser: William F. Elmquist.
Contained By:	Dissertation Abstracts International70-03B.
Subject:	Health Sciences, Pharmacology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3349765
ISBN:	9781109059755

Active transport and CNS delivery of novel tyrosine kinase inhibitors.
Chen, Ying.

Active transport and CNS delivery of novel tyrosine kinase inhibitors. - 209 p.

Adviser: William F. Elmquist.

Thesis (Ph.D.)--University of Minnesota, 2009.

Tyrosine kinase inhibitors (TKIs) are promising agents for specific inhibition of malignant cell growth and metastasis formation. They directly interfere with TK enzymes that are activated in tumor cells and are critical to tumor growth. The success of the first generation TKI, imatinib, in the treatment of CML has led to the broader examination of its application in the treatment of other tumors, such as glioma. However, early studies showed imatinib has difficulty penetrating blood-brain barrier (BBB). One component of the BBB that may limit the delivery of imatinib into the CNS is the drug efflux transporters, such as ABCB1 (p-glycoprotein) and ABCG2 (breast cancer resistance protein). Dasatinib is a second-generation TKI developed to overcome the molecular resistance to imatinib and may be very promising in the treatment of brain tumor. Thus far little information is known about the CNS delivery of dasatinib, including the action of relevant BBB transporters in modulating this delivery. The objectives of this work were to assess the influence of various drug efflux transporters, such as ABCB1 and ABCG2, on the specific delivery of imatinib and dasatinib to CNS and the possibility of improving CNS delivery of imatinib and dasatinib by effective pharmacological inhibition. In in vitro studies, we demonstrated that imatinib is a substrate of Abcg2 by using cellular accumulation and permeability methods. In in vivo studies, we further explored that ABCB1and ABCG2 together play an important role in limiting the CNS delivery of imatinib. Saturation or inhibition of ABCB1 and ABCG2 could effectively improve CNS delivery of imatinib.

ISBN: 9781109059755Subjects--Topical Terms:

1017717
Health Sciences, Pharmacology.

Active transport and CNS delivery of novel tyrosine kinase inhibitors.
LDR:03093nmm 2200277 a 45 001 887230
005 20101020
008 101020s2009 ||||||||||||||||| ||eng d
020 $a 9781109059755
035 $a (UMI)AAI3349765
035 $a AAI3349765
040 $a UMI $c UMI
100 1 $a Chen, Ying. $3 1058964
245 1 0 $a Active transport and CNS delivery of novel tyrosine kinase inhibitors.
300 $a 209 p.
500 $a Adviser: William F. Elmquist.
500 $a Source: Dissertation Abstracts International, Volume: 70-03, Section: B, page: 1610.
502 $a Thesis (Ph.D.)--University of Minnesota, 2009.
520 $a Tyrosine kinase inhibitors (TKIs) are promising agents for specific inhibition of malignant cell growth and metastasis formation. They directly interfere with TK enzymes that are activated in tumor cells and are critical to tumor growth. The success of the first generation TKI, imatinib, in the treatment of CML has led to the broader examination of its application in the treatment of other tumors, such as glioma. However, early studies showed imatinib has difficulty penetrating blood-brain barrier (BBB). One component of the BBB that may limit the delivery of imatinib into the CNS is the drug efflux transporters, such as ABCB1 (p-glycoprotein) and ABCG2 (breast cancer resistance protein). Dasatinib is a second-generation TKI developed to overcome the molecular resistance to imatinib and may be very promising in the treatment of brain tumor. Thus far little information is known about the CNS delivery of dasatinib, including the action of relevant BBB transporters in modulating this delivery. The objectives of this work were to assess the influence of various drug efflux transporters, such as ABCB1 and ABCG2, on the specific delivery of imatinib and dasatinib to CNS and the possibility of improving CNS delivery of imatinib and dasatinib by effective pharmacological inhibition. In in vitro studies, we demonstrated that imatinib is a substrate of Abcg2 by using cellular accumulation and permeability methods. In in vivo studies, we further explored that ABCB1and ABCG2 together play an important role in limiting the CNS delivery of imatinib. Saturation or inhibition of ABCB1 and ABCG2 could effectively improve CNS delivery of imatinib.
520 $a In vitro evidence pointed that dasatinib is a substrate of ABCB1 and Abcg2. In vivo results revealed that the CNS delivery of dasatinib was low. ABCB1 and ABCG2 could be a factor limiting the CNS delivery of dasatinib. ABCB1 plays a more important role than ABCG2 in effecting the CNS delivery of dasatinib. The use of potent inhibitors for both ABCB1 and ABCG2 can improve dasatinib CNS delivery. These findings provide significant insight into current and new clinical strategies to more effectively use the TKIs for CNS disease treatment and prevention.
590 $a School code: 0130.
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0419
710 2 $a University of Minnesota. $b Pharmaceutics. $3 1058963
773 0 $t Dissertation Abstracts International $g 70-03B.
790 $a 0130
790 1 0 $a Elmquist, William F., $e advisor
791 $a Ph.D.
792 $a 2009
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3349765